BioMarin Pharma (BMRN) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.83 -1.16%
EPS Growth %: +1,025.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +1,025.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.
- 2019 Full-Year Financial Guidance unchanged
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
